T cells are a fundamental component of the adaptive immune system. Ligation of the T cell antigen receptor (TCR) with antigenic peptide bound to major histocompatibility complex molecules on ...
Aptevo's CD3-engaging portfolio is anchored by mipletamig, a first-in-class CD123 x CD3 bispecific currently being evaluated in RAINIER, a Phase 1b/2 trial for frontline AML. In total, mipletamig has ...
The RAINIER study continues to enroll patients across additional dose levels. Mipletamig's design leverages Aptevo's ADAPTIR (TM) platform to deliver targeted T-cell engagement with the goal of ...
New candidates, APVO452 and APVO451, harness proprietary ADAPTIR-FLEX TM design to target prostate and multiple solid tumor cancers by simultaneously engaging tumor antigens, T cells, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback